PacBio (PACB) reports Q3: everything you need to know ahead of earnings

What happened

Pacific Biosciences of California will report earnings this Wednesday after market hours. Last quarter it reported revenue of $39.01 million, down 1.9% year on year, missing analysts' revenue expectations and significantly missing analysts' earnings per share estimates.

Confirmed

Global impact / market context

PacBio has missed Wall Street's revenue estimates several times over the past two years, so this report tests whether the expected 2.3% revenue growth arrives. A miss would reinforce doubts about demand for its gene-sequencing tools and could pressure the stock.

Analyst inference

Peers in life sciences tools have already reported: Illumina grew revenue 7.6% and beat estimates by 1.1%, while West Pharmaceutical grew 8.7% and beat by 5.7%. This sets a comparison for whether PacBio's expected 2.3% growth looks strong or weak.

Analyst inference

What to watch

1. Watch whether PacBio's revenue reaches the 2.3% year-on-year growth analysts expect this quarter, which would reverse the 3.8% decrease recorded in the same quarter last year. Confirmed
2. Watch earnings per share, which missed analysts' estimates significantly last quarter, alongside revenue that fell 1.9% year on year to $39.01 million. Confirmed
3. Watch management comments on tool demand and spending by research customers, since Illumina's 18.6% share drop after results signals investors may punish weak outlooks despite revenue beats. Analyst inference

Evidence

• stockstory.org